Fulminant post-transplant lymphoproliferative disorder presenting with lactic acidosis and acute liver failure.

  title={Fulminant post-transplant lymphoproliferative disorder presenting with lactic acidosis and acute liver failure.},
  author={R. Mathur and G. Kudesia and K. Suvarna and W. Mckane},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  volume={19 7},
  • R. Mathur, G. Kudesia, +1 author W. Mckane
  • Published 2004
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Post-transplant lymphoproliferative disorder (PTLD) is the most common non-cutaneous malignancy in solid organ transplant recipients and is associated with significant mortality. In renal transplant recipients the incidence has been estimated to be between 0.2 and 2.3% [1,2]. Most PTLD is driven by Epstein–Barr virus (EBV) infection. The risk of lymphoma in transplant recipients is up to 40 times that of the general population [1]. A spectrum of severity is seen and this reflects the degree of… Expand
A case of fulminant post‐transplant lymphoproliferative disorder and septicemia
The case of a 59‐yr‐old man who suffered from prolonged septicemia in the immediate post‐transplant period, and presented again four months after cardiac transplantation with fever, painful liver edge and gastrointestinal bleeding is described and urges for an aggressive diagnostic approach. Expand
Lymphoproliferative disorders in pediatric liver allograft recipients: a review of 212 cases.
Pediatric liver recipients developing PTLD have relatively better disease presentation and behavior than that in adults, and should be more intensively evaluated. Expand
Post-transplant lymphoproliferative disorder of the cervix.
Gynecologic oncologists need to be aware of this disease process when treating patients for gynecologic symptoms after transplant surgery as post-transplant complications can present in the female reproductive organs. Expand
Unusual Case of Severe Lactic Acidosis in a Liver Transplant Patient
The intention of presenting this case is to increase awareness of posttransplant lymphoma and propose lactic acidosis as not only an indicator of liver dysfunction or rejection but also an aid for diagnosis of this unusual but fatal and potentially curable condition. Expand


Pretransplantation assessment of the risk of lymphoproliferative disorder.
Pretransplantation determination of recipient EBV and CMV serostatus can identify a subgroup of patients whose risk for severe PTLD may preclude transplantation. Expand
Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
The overall incidence of PTLD has fallen from 10% to 5% for children receiving primary tacrolimus therapy after OLT, and serial monitoring of peripheral blood for Epstein Barr virus (EBV) by polymerase chain reaction (PCR) after pediatric OLT is recommended. Expand
Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation.
The data suggest that although EBV seronegativity does carry a 6.8-fold increase in the relative risk of developing PTLD, long-term survival despite the development of PTLD can be achieved, and thusEBV ser onegativity by itself should not be considered a contraindication to lung transplantation. Expand
Incidence of non-hodgkin lymphoma in kidney and heart transplant recipients
It is suggested that the risk of NHL is related to the aggressiveness of the immunosuppressive regimen, and in patients who received rejection prophylaxis with antilymphocyte antibodies there were significant increases in risk. Expand
It is hypothesized that risk factors for the development of posttransplant lymphoproliferative disorder may include heavy immunosuppression, including the use of OKT3, good DR matching, and active EBV infection. Expand
Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome
A combination of reducing immunosuppression, adding antiviral agents, and initiating CMV-IgG resulted in a significant reduction of EBV DNA levels in nine patients during the follow-up period, and there were no identifiable risk factors for developing elevatedEBV DNA PCR. Expand
A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events.
Immunosuppression decreased EBV-specific host immune function, which in turn favored increased EBV load in peripheral blood and increased excretion in the oropharynx. Expand
Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients.
The results suggest that the acquisition of donor EBV is a risk factor for PTLD development in a previously seronegative transplant recipient. Expand
Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients.
  • D. Liebowitz
  • Biology, Medicine
  • The New England journal of medicine
  • 1998
LMP1-mediated signaling through the TRAF system has a role in the pathogenesis of the EBV-positive lymphomas that arise in immunosuppressed patients. Expand
Rising incidence of post‐transplant lymphoproliferative disease in kidney transplant recipients
The purpose of this study was to determine whether the incidence of post‐transplant lymphoproliferative disease (PTLD) has been increasing in renal transplant recipients in this centre.